Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib for patients with acute lymphoblastic leukaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib under the National Health Act 1953, sections 85 and 100 for patients with acute lymphoblastic leukaemia (ALL).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib. It also sets the  maximum amount of treatment that can be approved.

Section 100 arrangements

Blinatumomab and inotuzumab ozogamicin

These items are only available for day admitted patients, non-admitted patient, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

These items aren’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Initial treatment

Blintumomab

Apply for initial (induction) authority approval to prescribe PBS subsidised blinatumomab for the treatment of ALL in writing and either:

All applications must include the completed:

You can make an application for a balance of supply by calling the PBS Complex Drugs Program enquiry line.

Patients must not receive more than 2 treatment cycles under the Initial (Induction) and Initial (Induction) - balance of supply restrictions.

Dasatinib

Apply for initial authority approval to prescribe PBS subsidised dasatinib for the treatment of ALL in writing and either:

All applications must include the completed:

Imatinib

Apply for initial authority approval to prescribe PBS subsidised imatinib for the treatment of ALL in writing and either:

All applications must include the completed:

Inotuzumab ozogamicin

Apply for initial (induction) applications for authority approval to prescribe PBS subsidised inotuzumab ozogamicin for the treatment of ALL in writing and either:

All applications must include the completed:

Ponatinib

Apply for initial authority approval to prescribe PBS subsidised ponatinib for the treatment of ALL in writing and either:

All applications must include the completed:

Initial grandfather treatment

Inotuzumab ozogamicin

For patients who received non-PBS subsidised inotuzumab ozogamicin treatment for ALL before 1 May 2019, apply for initial grandfather approval in writing and either:

All applications must include the completed:

Ponatinib

For patients who received non-PBS subsidised ponatinib treatment for ALL before 1 September 2018, apply for initial grandfather approval in writing and either:

All applications must include a completed:

Continuing treatment

To apply for continuing PBS subsidised TKI agents to treat  ALL, call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 May 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.